Enemeez, LLC dba Summit Pharmaceuticals

Form 483 issued July 29, 2021 · Phoenix, Arizona

Inspection
Jul 26 – Jul 29, 2021
Observations
3
Pages
3
FEI number
3005641023

In short: On July 29, 2021, FDA issued a Form 483 with 3 observations to Enemeez, LLC dba Summit Pharmaceuticals in Phoenix, Arizona (FEI 3005641023) after an inspection that ran Jul 26 – Jul 29, 2021. The investigators were James B. Arnett and Joel D. Hustedt. Most observations concern laboratory controls; the most-cited regulation is 21 CFR 211.166 (stability testing).

At a glance

3 of 3 observations on this 483 concern laboratory controls.

Laboratory controls3

What FDA observed

Preview: the opening words of each observation
  1. 01

    The written stability program for drug products does not…

  2. 02

    The written stability program for drug products does not describe the storage conditions for…

  3. 03

    The written stability testing…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Enemeez, LLC dba Summit Pharmaceuticals?

FDA listed 3 observations on this Form 483, mostly about laboratory controls. The most-cited regulation is 21 CFR 211.166 (stability testing). The opening words of each observation are shown on this page.

Who inspected Enemeez, LLC dba Summit Pharmaceuticals?

James B. Arnett and Joel D. Hustedt are named on this Form 483, for the inspection of Jul 26 – Jul 29, 2021. Each investigator has a profile showing what they cite most.

When was Enemeez, LLC dba Summit Pharmaceuticals inspected by FDA?

The inspection ran Jul 26 – Jul 29, 2021, and the Form 483 is dated July 29, 2021.

How do I get the full Form 483 for Enemeez, LLC dba Summit Pharmaceuticals?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free